Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin Add-On Therapy in T2DM with Metformin and Alogliptin
NCT07093476Phase 3Recruiting
- Sponsor
- Celltrion
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Celltrion. Started Jul 2025; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07093476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07093476.